(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/078955 A1

(51) International Patent Classification[7]: C12N 5/06, 7/02

(21) International Application Number:
PCT/EP2004/002067

(22) International Filing Date: 1 March 2004 (01.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0304799.0 3 March 2003 (03.03.2003) GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de L'institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AERTS, Brigitte, Ghislaine, Louise** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de L'institut 89, B-1330 Rixensart (BE). **GHISLAIN, Yves, Jules, Maurice** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de L'institut 89, B-1330 Rixensart (BE). **GONZE, Marie-Monique, Jane** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de L'institut 89, B-1330 Rixensart (BE). **KNOTT, Isabelle, Solange, Lucie** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de L'institut 89, B-1330 Rixensart (BE). **MAGGETTO, Carine** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de L'institut 89, B-1330 Rixensart (BE).

(74) Agent: **DALTON, Marcus, Jonathan, Wi**; GlaxoSmithKline (cn925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANIMAL-FREE CELL CULTURE METHOD

(57) Abstract: The present invention relates to a process for animal, preferably human, diploid anchorage-dependent cell culture, in the absence of exogenous components of primary animal origin, and to a cell culture medium substantially free of exogenous components of primary animal origin suitable for carrying out said process. In particular the invention concerns a cell culture medium which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal, preferably human diploid anchorage-dependent cells in a medium according to the invention, involving the use of a trypsin substitute of non-animal origin for passaging cells. The invention further relates to a process for producing viruses, viral vaccines and the like.

WO 2004/078955 A1